The results showed that patients who received semaglutide had a reduced risk of developing acute pancreatitis compared to the placebo group
Derived from the Body Protective Compound , it has shown effects in animal models on the GI tract, liver, pancreas, tendons/ligaments, muscle, cornea, heart, CNS, and nerves
Start your intake What Clinical Trials Show About Semaglutide Weight Loss SUSTAIN clinical trials demonstrated cumulative weight reduction of 9.3% at the 0.5 mg dose, 13.5% at 1 mg, and up to 15.3% at 2.4 mg over 68 weeks
Not better complementary
In the same trial, 1-8% of patients reported injection site reactions with retatrutide, while no case was reported in the placebo group